According to recent reports [29], [43], this subset comprises a minor fraction (under 1%) of the “bulk” of mature naïve CD19+CD27−IgM+CD21+ peripheral blood B cells, but may expand by a few percentage points in some (but not all) RA patients [29]. This evidence concerns the gene CD19 and rheumatoid arthritis.